On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the ...

We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset collaboration with Neurocrine Biosciences. Osavampator, formerly known as NBI ...

Neurocrine Biosciences amended its Takeda agreement, gaining exclusive global rights to osavampator for major depressive disorder. Phase 2 data for osavampator showed significant MADRS score ...

An announcement from Neurocrine ( (NBIX)) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive License Agreement with Takeda Pharmaceutical ...

Neurocrine Biosciences (NBIX) announced it has amended its agreement with Takeda (TAK) to develop and commercialize osavampator. Under the amended agreement, Neurocrine will obtain exclusive ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder. The San Diego ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24. Paul Matteis has given his Buy rating due to a combination of factors ...

The optimism follows an announcement by Neurocrine that they have altered their partnership with Takeda on the AMPA program, which includes the drug osavampator/NBI-845. With this amendment ...